HMGCR and neoplasm: As previously described, HMGCR is one of the rate-limiting enzymes for the cholesterol-producing mevalonate pathway, so targeting HMGCR may be a good strategy for tumor therapy (Nielsen et al., 2012; Gu et al., 2019; Di Bello et al., 2020).